- Home
- »
- Biotechnology
- »
-
Gene Synthesis Market Size, Share & Trends Report, 2033GVR Report cover
Gene Synthesis Market (2026 - 2033)
Size, Share & Trends Analysis Report By Method (Solid-phase Synthesis, Chip-based Synthesis, PCR-based Enzyme Synthesis), By Service, By Application, By End-use, By Region, And Segment Forecasts
Market Size, 2025
$2.7BMarket Estimate, 2026
$3.1BMarket Forecast, 2033
$9.3BCAGR, 2026–2033
16.7%Gene Synthesis Market Summary
The global gene synthesis market size was valued at USD 2.7 billion in 2025 and is projected to grow from USD 3.1 billion in 2026 to USD 9.3 billion by 2033, growing at a CAGR of 16.7% from 2026 to 2033. North America dominated the global market, accounting for the largest share of 37.5% in 2025. The growth of the market is attributed to factors such as favorable government policies relating to synthetic biology. Investors have been more focused on synthetic biology research during the past few years.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Key Market Trends & Insights
- By method: Solid-phase synthesis segment held the largest revenue share of 35.1% in 2025.
- By service: Antibody DNA synthesis segment held the largest revenue share of 60.9% in 2025.
- By application: Gene & cell therapy development segment held the largest revenue share of 35.2% in 2025.
- By end-use: Academic & government research institutes segment held the largest share of 54.4% in 2025.
Regional Highlights
- Largest regional market: North America (37.5% revenue share, 2025)
- By country: The U.S. held the largest share of North America in 2025.
Market Size & Forecast
- Market size in 2025: USD 2.7 Billion
- Estimated market size in 2026: USD 3.1 Billion
- Projected market size by 2033: USD 9.3 Billion
- CAGR (2026-2033): 16.7%
Prism AI by Grand View Research Free to tryAsk a question about the gene synthesis marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
The COVID-19 outbreak has driven significant growth in the gene synthesis market. Researchers are exploring untapped possibilities in the gene synthesis field, helping boost market growth and revenue generation. For instance, researchers at the National Institute of Standards and Technology have developed synthetic SARS-CoV-2 gene fragments to help develop accurate and reliable diagnostic tests for the disease. Advancements in synthetic DNA technology are gaining significant traction as a viable approach to address concerns associated with the growing number of emerging viruses and the potential threat of the next global pandemic. The SARS-CoV-2 pandemic, along with pandemics involving other novel diseases in the near future, can be rapidly addressed with the help of this promising technique to quickly replicate and analyze genes of interest.
To learn more about this report,Download Free Sample Report
Targeted therapy has gained significant interest from the biotechnology and pharmaceutical industry and researchers. It has become an important technique of disease management. Targeted therapy, in combination with immunotherapy and chemotherapy, is expected to grow significantly in the coming years. This would open up lucrative opportunities for both established and emerging players in the gene synthesis market.
The lack of skilled professionals in the field of gene synthesis and biotechnology is one of the main factors that could hinder the market growth, as the companies operating in this market would require trained and experienced staff at their facilities. Therefore, companies are entering into several strategic collaborations with universities to offer staff online workshops, on-site training, and sponsored projects to develop the right professionals. This would further help drive growth in the gene synthesis market.
Market Dynamics
The gene synthesis market is witnessing robust growth, driven by the increasing demand for synthetic genes in applications such as drug discovery, vaccine development, synthetic biology, and genetic engineering. Rising investments in genomics research, expanding adoption of personalized medicine, and growing use of gene synthesis in biopharmaceutical production are further supporting market growth. In addition, continuous advancements in DNA synthesis technologies, declining synthesis costs, and increasing research activities in cell and gene therapies are expected to support market expansion over the forecast period.
The rising demand for personalized medicine and precision therapeutics is a key factor driving the growth of the gene synthesis market. Personalized medicine relies on an individual's genetic profile to develop targeted therapies, diagnostics, and treatment strategies tailored to specific patient needs. Gene synthesis plays a critical role in enabling the rapid design and production of customized DNA sequences for applications such as biomarker discovery, companion diagnostics, and the development of advanced biologics. Moreover, the increasing prevalence of cancer, rare genetic disorders, and chronic diseases has accelerated the adoption of genomics-based approaches, thereby boosting the demand for synthetic genes across research and clinical applications.
According to a Wellcome article published in January 2025, large-scale genomic research and sequencing programs are significantly improving disease prediction, cancer treatment, and personalized healthcare outcomes. Such initiatives are anticipated to increase the utilization of gene synthesis technologies for target validation, therapeutic development, and biomarker identification, thereby contributing to the expansion of the gene synthesis market over the forecast period.
Biosecurity concerns associated with the potential misuse of synthetic DNA technologies are expected to restrain the growth of the gene synthesis market. Advances in gene synthesis have enabled the rapid and cost-effective production of customized DNA sequences; however, these capabilities also raise concerns regarding the unauthorized creation or modification of harmful pathogens. As a result, governments and regulatory authorities have implemented stringent oversight, screening protocols, and compliance requirements for gene synthesis providers.
Moreover, growing concerns about biosafety, ethical issues, and dual-use research have led to stricter regulations and monitoring of synthetic biology activities. While these measures are essential to ensuring the safe and responsible use of gene synthesis technologies, they can increase operational costs, extend approval timelines, and impose additional compliance burdens on market participants, thereby limiting market growth.
Analyst Perspective
The gene synthesis market is expected to witness strong growth, driven by increasing applications in synthetic biology, genetic engineering, vaccine development, and cell & gene therapy research. Rising demand for customized DNA constructs in drug discovery, protein engineering, and genomics research is accelerating the adoption of gene synthesis technologies. Technological advancements in DNA synthesis platforms, coupled with declining synthesis costs and growing investments in precision medicine and biotechnology research, are expected to support long-term market expansion. Market participants are focusing on automation, faster turnaround times, and high-fidelity synthesis solutions to strengthen their competitive position and address evolving research requirements.
Method Insights
By method, the solid-phase synthesis segment accounted for the largest revenue share in 2025, at 35.1%, due to the increasing adoption rate over the past few years. This is a prominent technology for applications across several fields and for various research purposes, as it can be used to create modified & canonical nucleic acid polymers, specifically RNA or DNA.
Most companies currently offering commercial gene synthesis services use a solid-phase synthesis process, employing various platforms from companies such as Twist, Telesis Bio, DNA Script, and Ansa.
The PCR-based enzyme segment is expected to register the fastest CAGR during the forecast period. Certain factors, such as its precision, ease of use, and reasonably priced technology, are the factors estimated to accelerate segment growth by 2033. It is an effective method to produce the A+T-rich malaria genome.
Moreover, PCR-based gene synthesis provides a simple solution to the issue of producing significant amounts of labeled protein for NMR spectroscopy when the gene encoding the protein is difficult or unavailable to express effectively. Thus, the aforementioned applications of this technique are contributing to segment growth.
Service Insights
By service, the antibody DNA synthesis segment accounted for the largest revenue share, at 60.9%, in 2025. The presence of several market players offering antibody DNA synthesis services has contributed to the dominance of the gene synthesis market in 2025. Companies are providing services to research institutions and biotech/pharma companies to enable cloning and synthesis of antibody chain sequences into any vector.
In April 2022, Twist Bioscience Corporation announced the launch of a high-throughput antibody production platform. Customers can convert digital DNA (dDNA) sequences into purified IgG antibodies using the antibody production workflow. In June 2022, Telesis Bio (formerly Codex DNA) presented automated synthetic biology technologies to accelerate discovery workflows at the conference on antibody engineering and therapeutics in Europe.
Viral gene synthesis is projected to witness the fastest growth rate owing to the growing virus vector-related R&D activities. Furthermore, companies are involved in the synthesis of all structural and non-structural gene fragments or protein genes of the SARS-CoV-2. In February 2022, Eleven Therapeutics and Twist Bioscience Corporation developed a replicon tool to examine viral genome replication, screen for antiviral drugs, and support therapeutic & vaccine development.
Application Insights
By application, the gene & cell therapy development segment accounted for the largest revenue share in 2025, at 35.2%. This is anticipated to expand the advanced therapies pipeline for the treatment of chronic diseases. These therapies are gaining significant acceptance among therapy developers due to their efficiency in treating diseases that were not treatable using the traditional mode of treatment.
Several initiatives have been undertaken by biotechnology and pharmaceutical companies to promote cell and gene therapy treatments. In January 2022, Century Therapeutics entered into a collaboration with Bristol Myers Squibb Company to develop iPSC-derived allogeneic cell therapies.
Disease diagnosis is expected to see the fastest growth rate in the coming years, owing to the growing disease burden worldwide and a rising need for improvements in medical diagnostics. Synthetic biology provides biomolecular engineering strategies that can go beyond the limitations of traditional antibody-based diagnostic platforms, which are usually slow, expensive, and ill-suited to the testing emerging pathogens or rare diseases.
Moreover, the increasing adoption of advanced techniques that drive scientific progress, such as the production of designer cells that can employ synthetic gene circuits to detect disease biomarkers and aid in diagnosis, is also contributing to the segment’s growth.
End-use Insights
By end use, the academic and government research institutes segment held the largest revenue share, over 54.0%, in 2025, and is expected to grow at the fastest CAGR over the forecast period. The research institutes are entering into collaborations with service providers to speed up their research programs that require the characterization and synthesis of gene fragments.
To learn more about this report,Download Free Sample Report
For instance, in February 2021, the Medicines Manufacturing and Innovation Center collaborated with Exactmer, Novartis, UK Research & Innovation, and AstraZeneca. This collaboration aims to develop a sustainable, scalable, and cost-effective manufacturing process for oligonucleotides.
Biotechnology and pharmaceutical companies are projected to witness significant growth in the coming years. Key players are also focusing on the development and launch of new platforms that can enhance the gene synthesis process. For instance, in August 2020, Codex DNA launched the BioXp 3250 system for the synthetic biology workflow. This platform aims to accelerate the development of new biologics and vaccines. It allows researchers to generate large DNA fragments of up to 7kb at high speed without compromising accuracy. These factors would further contribute to the segment’s growth.
Regional Insights
North America dominated the gene synthesis market with the largest revenue share of 37.5% in 2025. This can be attributed to the presence of several key market players offering gene synthesis services, increasing interest of major biotechnology & pharmaceutical companies in gene & cell therapy development, the expanding field of synthetic biology in the region, and increasing interest in gene synthesis in the molecular biology arena.
To learn more about this report,Download Free Sample Report
Furthermore, the presence of numerous contract research organizations (CROs) providing gene synthesis services is expected to increase revenue in the region. For instance, GenScript has established a significant presence across the North American region. It offers a broad range of services, including antibody drug development services and custom gene synthesis services
Asia Pacific is projected to witness the fastest growth rate during the forecast period due to increasing research activities for the development of effective therapeutics, coupled with increasing interest in synthetic biology research. In addition, there is a rising incidence of lifestyle-related diseases. Improving healthcare infrastructure, the entry of large biotechnology organizations, and growing R&D activities are also expected to contribute to market growth.
Key Companies & Market Share Insights
Key players operating in the market are taking several strategic initiatives, such as entering into collaborations and partnerships, and expanding into favorable regions. Companies are introducing novel products to strengthen their product portfolio in the market. For instance, in March 2022, ProteoGenix launched the XtenCHO Transient CHO Expression System.
This product simplifies recombinant protein production, further accelerating early-phase drug screening. Similarly, in February 2022, Integrated DNA Technologies, Inc. announced the introduction of Alt-R HDR Donor Blocks, which enable precise HDR-based genome edits.
Key Gene Synthesis Companies
The following key companies have been profiled for this study on the gene synthesis market.
-
GenScript
-
Azenta Life Sciences (GENEWIZ)
-
Boster Biological Technology
-
Twist Bioscience
-
ProteoGenix, Inc.
-
Biomatik
-
ProMab Biotechnologies, Inc.
-
Thermo Fisher Scientific, Inc.
-
Integrated DNA Technologies, Inc.
-
OriGene Technologies, Inc.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (GenScript, Twist Bioscience, Thermo Fisher Scientific, Integrated DNA Technologies, etc.)
Focus on expanding synthetic biology and gene synthesis capabilities through advanced DNA synthesis technologies, automation, and high-throughput manufacturing platforms.
Strong technological expertise, scalable manufacturing capabilities, and broad service portfolios covering gene synthesis, oligonucleotide synthesis, and related genomic services.
High dependence on research funding and biotechnology R&D spending.
Emerging Players (Boster Biological Technology, ProteoGenix, Biomatik)
Focus on specialized gene synthesis, custom molecular biology services, and niche applications, including recombinant proteins, antibodies, and customized genetic constructs.
Strong specialization in customized research services and the ability to address specific customer requirements.
Limited global scale and lower financial resources than large, integrated competitors.
Recent Developments
-
In May 2026, Twist Bioscience expanded its Clonal Genes portfolio with the early-access launch of Complex Genes, enabling the synthesis of structurally complex and highly engineered protein sequences. The new capability is designed to increase acceptance of complex gene orders and support applications in AI-enabled drug discovery and nucleic acid therapeutics.
-
In January 2026, Integrated DNA Technologies entered into a strategic collaboration with Ansa Biotechnologies to offer Ansa's Clonal DNA and XL Clonal DNA products, ranging from 100 base pairs to 50 kilobases. The collaboration expands IDT's synthetic biology portfolio and enables researchers to obtain longer, more complex, sequence-verified DNA constructs for cell and gene therapy, vaccine research, and agrigenomics applications.
Gene Synthesis Market Report Scope
Report Attribute
Details
Market size in 2025
USD 2.7 billion
Estimated market size in 2026
USD 3.1 billion
Projected market size by 2033
USD 9.3 billion
Growth rate
CAGR of 16.7% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Method, services, application, end-use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Denmark, Sweden, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, Saudi Arabia, South Africa, UAE, and Kuwait
Key companies profiled
GenScript; Azenta Life Sciences (GENEWIZ); Boster Biological Technology; Twist Bioscience; ProteoGenix, Inc.; Biomatik; ProMab Biotechnologies, Inc.; Thermo Fisher Scientific, Inc.; Integrated DNA Technologies, Inc.; OriGene Technologies, Inc.
Customization scope
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Gene Synthesis Market Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global gene synthesis market report based on the method, service, application, end-use, and region:
-
Method Outlook (Revenue, USD Million, 2021 - 2033)
-
Solid-phase Synthesis
-
Chip-based Synthesis
-
PCR-based Enzyme Synthesis
-
-
Services Outlook (Revenue, USD Million, 2021 - 2033)
-
Antibody DNA Synthesis
-
Viral DNA Synthesis
-
Others
-
-
Application Outlook (Revenue, USD Million, 2021 - 2033)
-
Gene & Cell Therapy Development
-
Vaccine Development
-
Disease Diagnosis
-
Others
-
-
End-use Outlook (Revenue, USD Million, 2021 - 2033)
-
Biotechnology & Pharmaceutical Companies
-
Academic & Government Research Institutes
-
Contract Research Organizations
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
Germany
-
U.K.
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The gene synthesis market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing, reconciling supply-side and demand-side estimates, and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each gene synthesis segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment- Method
Revenue Capture Definition
Solid-phase Synthesis
Revenue generated from gene synthesis technologies that employ solid supports for the stepwise assembly of oligonucleotides and synthetic genes. These methods are widely used to produce customized DNA sequences with high accuracy and scalability, supporting applications in synthetic biology, therapeutic development, vaccine research, and molecular biology.
Chip-based Synthesis
This segment captures income from high-throughput gene synthesis approaches that utilize microarray or chip-based platforms to simultaneously synthesize large numbers of oligonucleotides. Such technologies enable cost-effective and parallel production of DNA constructs for large-scale genomics, synthetic biology, and research applications.
PCR-based Enzyme Synthesis
Market value in this category stems from gene synthesis methods that leverage enzymatic amplification and polymerase chain reaction (PCR) techniques to assemble and amplify synthetic DNA fragments. These approaches are widely used to generate long, complex gene sequences required for research, diagnostics, and therapeutic development.
Segment- Service
Revenue Capture Definition
Antibody DNA Synthesis
Revenue originates from custom gene synthesis services focused on designing and synthesizing DNA sequences encoding antibodies, antibody fragments, and engineered antibody constructs. These services support monoclonal antibody discovery, therapeutic antibody development, immunotherapy research, and biologics manufacturing.
Viral DNA Synthesis
This segment reflects earnings from synthesis services involving viral genes, genomes, and related DNA constructs used in vaccine development, virology research, vector engineering, and gene therapy applications.
Others
Includes revenue derived from additional gene synthesis services not categorized under antibody or viral DNA synthesis, such as synthetic pathway engineering, gene optimization, plasmid construction, codon optimization, and customized DNA construct development for research and industrial applications.
Segment- Application
Revenue Capture Definition
Gene & Cell Therapy Development
Revenue generated from gene synthesis products and services used in the development of gene therapies, engineered cell therapies, and genome-editing applications. Synthetic genes support vector construction, target validation, cell engineering, and therapeutic candidate development for advanced treatment modalities.
Vaccine Development
This segment captures income from synthetic DNA technologies used in the design and production of vaccine candidates, including DNA, mRNA, and recombinant vaccines, as well as next-generation immunization platforms targeting infectious diseases and emerging pathogens.
Disease Diagnosis
Market value in this category stems from gene synthesis applications that support molecular diagnostics, assay development, biomarker identification, and validation of diagnostic tests for disease detection and clinical research.
Others
Revenue originates from gene synthesis applications in synthetic biology, agricultural biotechnology, industrial biotechnology, protein engineering, metabolic engineering, and other emerging research areas.
Segment- End Use
Revenue Capture Definition
Biotechnology and Pharmaceutical Companies
Revenue generated from gene synthesis products and services procured by biotechnology and pharmaceutical organizations for drug discovery, biologics development, synthetic biology research, vaccine production, and development of advanced therapeutics.
Academic and Government Research Institutes
This segment represents income derived from gene synthesis technologies used by universities, government laboratories, and public research organizations conducting basic, translational, and applied life sciences research.
Contract Research Organizations
Market demand in this category is driven by contract research organizations that use gene synthesis services to support outsourced research, preclinical studies, therapeutic development, assay development, and customized molecular biology projects for biopharmaceutical clients.
Estimation Model
Layer Name
Key Question
Description
Commodity Flow Analysis
How was the overall market size estimated?
Market size was estimated by analyzing revenues generated by key gene synthesis service providers and synthetic DNA manufacturers, supported by company annual reports, investor presentations, service portfolios, and premium industry databases. Revenue contributions from private and regional companies were assessed through secondary sources and validated through primary interviews to derive the overall market value.
Parent Market & Penetration-Based Analysis
How was the gene synthesis market evaluated within the broader DNA synthesis market?
The gene synthesis market was evaluated within the broader DNA synthesis market. Adoption rates of gene synthesis technologies across synthetic biology, drug discovery, vaccine development, protein engineering, agricultural biotechnology, and academic research were analyzed to estimate the addressable market and segment-level opportunities.
Country-Level Segment Share Modeling
How were country-level segment shares derived?
Market shares for synthesis method, service, application, and end-use segments were derived using country-specific biotechnology R&D expenditure, genomic research activity, synthetic biology adoption, biopharmaceutical development intensity, and funding for life sciences research. Weighted average calculations were applied to determine regional and global segment distributions.
Data Triangulation & Validation Model
How were the market estimates validated?
Market estimates were validated through triangulation of secondary research, primary interviews, company-level revenue assessments, demand analysis across end-use industries, and technology adoption trends, ensuring consistency and accuracy across all market segments and geographies.
Forecasting & CAGR Modeling
How were market forecasts and CAGR developed?
Market forecasts were developed using historical demand trends in synthetic biology, increasing genomic and proteomic research, expansion of cell and gene therapy pipelines, growth in vaccine and biologics development, and technological advancements in DNA synthesis platforms. Regression-based analysis and trend modeling were applied to project future market growth and CAGR.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Cross-Segmentation Analysis for Gene Synthesis Applications & End Users
Detailed cross-segmentation analysis across gene synthesis applications, including gene & cell therapy development, vaccine development, disease diagnosis, and other applications by end users such as biotechnology & pharmaceutical companies, academic & government research institutes, and CROs.
Assessment of adoption trends across synthesis methods and service categories at regional and country levels.
Enables clients to identify high-growth application-end user combinations, evaluate demand patterns across research and commercial settings, prioritize target customer groups, and uncover emerging revenue opportunities across the gene synthesis value chain.
Technology & Service Benchmarking for Gene Synthesis Platforms
Comprehensive assessment of gene synthesis technologies, including solid-phase synthesis, chip-based synthesis, and PCR-based enzyme synthesis, along with service benchmarking across antibody DNA synthesis, viral DNA synthesis, and other synthesis services.
Includes evaluation of turnaround time, synthesis accuracy, throughput capabilities, pricing trends, and technological advancements across leading market participants.
Supports strategic product positioning, identifies technology gaps and innovation opportunities, benchmarks service competitiveness, and helps clients optimize portfolio development and commercialization strategies.
Regional Demand & Competitive Intelligence Assessment for Gene Synthesis Market
Customized regional and country-level analysis covering demand for gene synthesis services across North America, Europe, Asia Pacific, Latin America, and MEA.
Includes evaluation of synthetic biology funding, gene therapy pipeline activity, research infrastructure, regulatory environment, and competitive landscape across key countries.
Help clients identify high-growth geographies, assess market attractiveness, prioritize expansion markets, align regional strategies with research funding trends, and support investment and partnership decisions.
Frequently Asked Questions About This Report
The global gene synthesis market size was valued at USD 2.7 billion in 2025 and is expected to reach USD 3.1 billion in 2026.
The global gene synthesis market is expected to grow at a compound annual growth rate of 16.7% from 2026 to 2033 to reach USD 9.3 billion by 2033.
Some of the prominent players in the gene synthesis market include GenScript, Azenta Life Sciences (GENEWIZ), Boster Biological Technology, Twist Bioscience, ProteoGenix, Inc., Biomatik, ProMab Biotechnologies, Inc., Thermo Fisher Scientific, Inc., Integrated DNA Technologies, Inc., and OriGene Technologies, Inc.
The declining price of DNA synthesis & sequencing, the advent of the enzymatic DNA synthesis process, and technological advancements in the DNA synthesis platforms are driving the gene synthesis market growth.
The antibody DNA synthesis segment held the largest revenue share of over 60.9% in 2025.
The gene & cell therapy development segment held the largest revenue share of over 35.2% in 2025.
The academic and government research institutes segment held the largest revenue share of over 54.4% in 2025, and it is expected to grow with the fastest CAGR over the forecast period.
North America dominated with a 37.5% revenue share in 2025.
The solid-phase synthesis method accounted for the largest revenue share of 35.1% in 2025 owing to its high accuracy and higher adoption rate over the past years.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.